Highlights Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.73 ^CAD	+0.70%		+0.17%	+10.40%

Mar. 22	Knight Therapeutics Price Target Raised to $7 at RBC	MT
Mar. 21	Knight Therapeutics Reports Fourth Quarter Results	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Knight Therapeutics Reports Fourth Quarter Results	Mar. 21	MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	Mar. 21	CI
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Knight Therapeutics Announces Launch of Minjuvi in Brazil	Feb. 29	MT
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil	Feb. 29	MT
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil	Feb. 21	MT
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil	Feb. 21	CI
Knight Therapeutics Announces Launch of Bijuva in Canada	Feb. 06	MT
Knight Therapeutics Brief: Announcing Launch of Bijuva in Canada	Feb. 06	MT
Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada	Feb. 06	CI
Knight Therapeutics Enters Into License Agreement With Amneal Pharmaceuticals For Parkinson's Disease Treatment	Jan. 25	MT
Knight Therapeutics Brief: Entering Into Exclusive License Agreement With Amneal Pharmaceuticals For IPX203	Jan. 25	MT
Knight Therapeutics Announces Product Launch For IMVEXXY In Canada	Jan. 04	MT
Knight Therapeutics Inc. Announces Product Launch for IMVEXXY in Canada	Jan. 04	CI
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada	Dec. 19	MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada	Dec. 19	MT
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	Dec. 19	CI
Knight Therapeutics in Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	Dec. 19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Highlights

Filters